替罗非班在急性心肌梗死介入术后患者中的临床应用

Clinical application of tirofiban in patients with acute myocardial infarction underwent percutaneous intervention

目的观察替罗非班在急性心肌梗死患者急诊介入术的临床效果和安全性。方法符合急性心肌梗死入选标准的患者60例，随机分为试验组（n=40）和对照组（n=20）。试验组以微量泵持续泵入替罗非班，对照组以微量泵持续泵入肝素。所有患者均口服阿司匹林、氯吡格雷，皮下注射低分子肝素。疗程均为2～3d。观察2组心电图改变、血小板聚集率、主要终点事件（顽固性缺血状态、再发心肌梗死和死亡）及不良反应发生情况。结果与对照组相比，试验组心电图缺血性改变有明显好转（P〈0．01）；血小板聚集率明显下降（P〈0．01）；主要终点事件发生率有下降趋势，无严重不良反应。结论替罗非班对急诊介入治疗急性心肌梗死患者是安全有效的。

Objective To observe the clinical effect and safety of tirofiban in patients with acute myocardial infarction underwent percutaneous intervention （PCI）.Methods 60 patients with acute myocardial infarction underwent PCI were randomly divided into two groups.dO patients in experimental group were treated with trofiban, while 20 patients in control group were treated with heparin for 2 - 3 days. The changes of electrocardiography （ECG）, platelet aggregation rate,the primary end point events（persistent myocardial ischemie state, new onset myocardial infarction and death ） and adverse reactions of drugs were observed.Results Compared with that in control group, the ECG was significantly improved in tirofiban group （ P 〈 0.01 ）, and the platelet aggregation rate was obviously decreased （ P 〈 0.01 ） and the tendency of primary composite end point events was reduced. Conclusion Tirofiban is effective and safe in treating patients with acute myocardial infarction underwent PCI.